A Dosing Study of Bevacizumab for Retinopathy of Prematurity: Late Recurrences and Additional Treatments.

ABSTRACT:

Purpose

Intravitreal bevacizumab is increasingly used to treat severe retinopathy of prematurity (ROP), but it enters the bloodstream, and there is concern that it may alter development of other organs. Previously we reported short-term outcomes of 61 infants enrolled in a dose de-escalation study, and we report the late recurrences and additional treatments.

Design

Masked, multicenter, dose de-escalation study.

Participants

A total of 61 premature infants with type 1 ROP.

Methods

If type 1 ROP was bilateral at enrollment, then the study eye was randomly selected. In the study eye, bevacizumab intravitreal injections were given at de-escalating doses of 0.25 mg, 0.125 mg, 0.063 mg, or 0.031 mg; if needed, fellow eyes received 1 dose level higher: 0.625 mg, 0.25

SUBMITTER: Wallace DK 

PROVIDER: S-EPMC6402322 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature